Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2011;11(1):77-83.
doi: 10.2165/11590310-000000000-00000.

Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor

Mohammad Niazi  1 , Stanko Skrtic, Magnus Ruth, Ann A Holmberg
Affiliations
Clinical Trial

Pharmacokinetic profile of lesogaberan (AZD3355) in healthy subjects: a novel GABA(B)-receptor agonist reflux inhibitor

Mohammad Niazi et al. Drugs R D. 2011.

Abstract

Background: Lesogaberan (AZD3355) is a novel reflux inhibitor developed as an add-on treatment to proton pump inhibitors (PPIs) for symptom relief in patients with gastroesophageal reflux disease who have a partial response to PPI therapy.

Objective: The aim of this study was to evaluate the pharmacokinetic profile of lesogaberan in healthy subjects after single oral and intravenous administration of (14)C-labeled lesogaberan and non-(14)C-labeled lesogaberan.

Study design: This was an open-label, single-center, randomized, two-way crossover, phase I study.

Participants: Ten healthy male subjects took part in the study.

Intervention: Volunteers were randomized to receive a single dose of either orally dosed (100 mg) or intravenously infused (20 mg) non-(14)C-labeled lesogaberan, and then orally (100 mg) or intravenously (20 mg) administered (14)C-labeled lesogaberan in a crossover design. Treatment periods were separated by a washout period of at least 7 days.

Main outcome measures: Analyses of the rate and route of excretion, dose recovery, area under the plasma concentration versus time curve (AUC), AUC to the last quantifiable concentration, maximal plasma concentration (C(max)), time to C(max), the apparent elimination half-life, bioavailability, total clearance, renal clearance, fraction of the bioavailable dose excreted unchanged in the urine, cumulative amount of drug excreted unchanged in urine, and the apparent volume of distribution at steady state of lesogaberan.

Results: Lesogaberan was rapidly and extensively absorbed from the gastrointestinal tract and C(max) was achieved within 1-2 hours of oral dosing. The terminal half-life of lesogaberan was between 11 and 13 hours. Renal clearance accounted for approximately 22% of total body clearance. Based on the recovery of administered radioactivity, approximately 84% of the dose was excreted into the urine either as the parent compound or as water-soluble metabolite(s). There were no safety concerns raised during the study.

Conclusion: Orally administered lesogaberan is rapidly absorbed with high bioavailability and the majority of the dose is excreted by the kidneys either as the parent compound or as metabolites. The major elimination pathway for lesogaberan in man is metabolism.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design. = intravenous; R = randomization.
Table I
Table I
Subject baseline characteristics (n = 10)
Table II
Table II
Estimated geometric means and 95% CIs for the pharmacokinetic variables of lesogaberan (n = 10)
Table III
Table III
Estimated geometric means and ranges for the pharmacokinetic variables of 14C-labeled lesogaberan dosed orally (n = 5) and intravenously (n = 5)
Fig 2
Fig 2
Mean (± SD) plasma concentration versus time profiles of orally (100 mg) and intravenously (20 mg) administered 14C-labeled lesogaberan (n = 5).
Table IV
Table IV
Number of subjects with adverse events after oral and intravenous administration of 14C-labeled and non-14C-labeled lesogaberan (n = 10)a
See this image and copyright information in PMC

References

    1. Lidums I, Lehmann A, Checklin H, et al. Control of transient lower esophageal sphincter relaxations and reflux by the GABAB agonist baclofen in normal subjects. Gastroenterology. 2000;118(1):7–13. doi: 10.1016/S0016-5085(00)70408-2. - DOI - PubMed
    1. van Herwaarden MA, Samsom M, Rydholm H, et al. The effect of baclofen on gastro-oesophageal reflux, lower oesophageal sphincter function and reflux symptoms in patients with reflux disease. Aliment Pharmacol Ther. 2002;16(9):1655–62. doi: 10.1046/j.1365-2036.2002.01325.x. - DOI - PubMed
    1. Lehmann A, Jensen JM, Boeckxstaens GE. GABAB receptor agonism as a novel therapeutic modality in the treatment of gastroesophageal reflux disease. Adv Pharmacol. 2010;58:287–313. doi: 10.1016/S1054-3589(10)58012-8. - DOI - PubMed
    1. Lehmann A, Antonsson M, Holmberg AA, et al. (R)-(3-amino-2-fluoropropyl) phosphinic acid (AZD3355), a novel GABAB receptor agonist, inhibits transient lower esophageal sphincter relaxation through a peripheral mode of action. J Pharmacol Exp Ther. 2009;331(2):504–12. doi: 10.1124/jpet.109.153593. - DOI - PubMed
    1. Boeckxstaens GE, Rydholm H, Lei A, et al. Effect of lesogaberan, a novel GABAB-receptor agonist, on transient lower oesophageal sphincter relaxations in male subjects. Aliment Pharmacol Ther. 2010;31(11):1208–17. doi: 10.1111/j.1365-2036.2010.04283.x. - DOI - PubMed

Publication types

MeSH terms